Metabolic Syndrome and Insulin Resistance at Allina (MISURA)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by Allina Health System.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Greg Plotnikoff, Allina Health System Identifier:
First received: February 28, 2012
Last updated: March 6, 2012
Last verified: March 2012

Vitamin D deficiency is widespread and appears to represent one easily and inexpensively modifiable risk factor for diabetes and cardiovascular disease. More than 40 years of data link hypovitaminosis D to metabolic syndrome, insulin resistance, hyperglycemia, type 2 diabetes and increased cardiovascular risk.

Screening for vitamin D deficiency followed by supplementation in appropriate individuals could be among the simplest and most cost-effective measures for reducing metabolic syndrome and insulin resistance in the general population.

This study will test the hypothesis that increasing vitamin D status in vitamin D deficient individuals with metabolic syndrome will:

  1. reduce multiple serum cardiometabolic risk factors for both diabetes and cardiovascular disease,
  2. stabilize or reverse the stage of pre-diabetes,
  3. improve quality of life, and,
  4. improve the ability to make health-related behavioral changes.

Condition Intervention Phase
Metabolic Syndrome
Dietary Supplement: vitamin D3 (cholecalciferol)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Randomized, Controlled Trial of Vitamin D Replenishment in Metabolic Syndrome

Resource links provided by NLM:

Further study details as provided by Allina Health System:

Primary Outcome Measures:
  • insulin resistance score by NMR lipid fractionation [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    additional insulin resistance measure

  • Reynolds Risk Score [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The Reynolds Risk Score is designed to predict one's risk of having a future heart attack, stroke, or other major heart disease in the next 10 years. In addition to your age, blood pressure, cholesterol levels and whether you currently smoke, the Reynolds Risk Score uses information from two other risk factors, a blood test called hsCRP (a measure of inflammation) and whether or not either of your parents had a heart attack before they reached age 60 (a measure of genetic risk).

  • Pre-diabetes stage [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The pre-diabetes stage, a marker of progression toward type 2 diabetes mellitus, is a calculated score based upon results of fasting adiponectin, insulin and proinsulin.

Secondary Outcome Measures:
  • 25-OH-vitamin D [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    25-OH-vitamin D is the best measure of vitamin D status.

  • fasting lipid profile [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • adiposity markers [ Time Frame: 6 months ] [ Designated as safety issue: No ]

    Adiponectin: This adipocyte-derived protein increases hepatic and peripheral insulin sensitivity, moderates fat tissue growth, decreases lipid and glucose production in the liver and suppresses vascular inflammation. This measure declines as insulin resistance increases.

    Leptin: This adipocyte-derived hormone plays a key role in regulating neuroendocrine and immune function, appetite, metabolic rate and body weight. Many overweight individuals have elevated levels and leptin resistance.

  • TNF-alpha [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Inflammatory markers: TNF-alpha, IL-6, IL-8. These inflammatory mediators are central to the pathophysiology of obesity and its systemic effects

  • weight [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • blood pressure [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • PROMIS-29 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    PROMIS is a questionnaire data bank developed and made available by the National Institutes of Health for research purposes. It is used to measure the core domains of physical functioning, fatigue, pain, depression, anxiety, and social role participation.

  • Perceived Stress Scale (PSS) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The PSS is brief, validated and widely used psychological instrument for assessing a participant's perception of stress. The PSS-4 consists of 4 questions to measure the degree to which situations in the participant's life are perceived as stressful including questions related to perceived unpredictability and lack of control.

  • WPAI [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    This 6 item, validated instrument measures work and general activity impairment due to health problems. It uses a seven day recall and has been adapted for use in populations with differing health problems.

  • PROMIS-GH [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    PROMIS is a questionnaire data bank developed and made available by the National Institutes of Health for research purposes. The PROMIS-GH consists of 10 items, representing multiple domains and can be scored into a Global Physical Health component and a Global Mental Health component

  • International Physical Activity Questionnaire (IPAQ) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The International Physical Activity Questionnaire (IPAQ) short form (4 generic items) versions for use by either telephone or self-administered methods are available. The purpose of the questionnaire is to provide a common instrument that can be used to obtain internationally comparable data on health related physical activity. The development of this international measure for physical activity commenced in Geneva in 1998 and was followed by extensive reliability and validity testing undertaken in 12 countries (14 sites) across 6 continents during 2000.

  • IL-6 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Inflammatory mediators, including IL-6, are central to the pathophysiology of obesity and its systemic effects.

  • IL-8 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Inflammatory mediators, inlcuding IL-8, are central to the pathophysiology of obesity and its systemic effects.

  • HS-CRP [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Elevated HS-CRP predicts the development of type II diabetes and is a crucial factor in calculating the Reynolds Risk Score.

  • Lp-PLA2 (PLAC) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    This is an enzyme produced by inflammatory cells that hydrolyzes oxidized phospholipids in HDL and catalyzes the degradation of PAF, platelet activating factor. Levels are positively correlated with increased risk of developing coronary artery disease and stroke.

  • PAI-1 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    This is the primary inhibitor of plasminogen activation. Elevated levels predispose to clot formation by inhibiting fibrinolytic activity.

  • Fibrinogen [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Fibrinogen is also known as coagulation Factor I. Elevated levels are associated with cardiovascular disease. This is an acute-phase protein that is elevated in any form of inflammation.

Estimated Enrollment: 200
Study Start Date: March 2012
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Regular Dose
Intervention: 600 IUs of cholecalciferol taken by mouth daily.
Dietary Supplement: vitamin D3 (cholecalciferol)
Active intervention: 6,000 IUs taken by mouth daily for 6 months Active Comparator: 600 IUs taken by mouth daily for 6 months
Other Name: D-Drops
Experimental: High Dose D
Intervention: 6,000 IUs of cholecalciferol taken by mouth daily.
Dietary Supplement: vitamin D3 (cholecalciferol)
Active intervention: 6,000 IUs taken by mouth daily for 6 months Active Comparator: 600 IUs taken by mouth daily for 6 months
Other Name: D-Drops

Detailed Description:

Longitudinal observational studies suggest a significant inverse association between vitamin D status and both incident and prevalent metabolic syndrome/type II diabetes. Results from small underpowered trials and post-hoc analyses of data from larger trials designed for bone-specific outcomes suggest that vitamin D may slow the progression to diabetes in adults with glucose intolerance. However, at this time, no randomized trials of sufficient size exist to assess effectiveness.

Importantly, in the investigators' own study of over 10,000 Allina employees, the investigators found that 6% of these employees had levels less than 10 ng/mL, 30% less than 20 ng/ml and 60% less than 30 ng/ml. Recently, the Intermountain Heart Collaborative Study Group reviewed 41,504 patient records with at least one measured vitamin D level. Surprisingly, both the Intermountain and the Allina Employee study demonstrate vitamin D deficiency (≤30 ng/ml) in more than 60% of people tested with only minor differences by gender or age (Plotnikoff GA, Finch M, Dusek JA. Impact of Vitamin D Deficiency on the Productivity of a Health Care Workforce. J Occup Environ Med (in press)).

Furthermore, the Intermountain group demonstrated that vitamin D levels less than 30 ng/ml, compared to levels greater than 30 ng/ml, were associated with highly significant (p <0.0001) increases in the prevalence of diabetes, hypertension, hyperlipidemia, and peripheral vascular disease. Also, those without risk factors but with severe deficiency had an increased likelihood of developing diabetes, hypertension, and hyperlipidemia. The vitamin D levels were also highly associated with coronary artery disease, myocardial infarction, heart failure, and stroke (all p <0.0001), as well as with incident death, heart failure, coronary artery disease/myocardial infarction (all p <0.0001), stroke (p = 0.003), and their composite (p <0.0001).

Numerous prevention efforts are underway to minimize the predicted economic and human burdens from these increasingly common diseases. However, few, if any, prospective clinical trials are underway with vitamin D interventions. This trial is specifically designed to prospectively test the impact of vitamin D replenishment on both metabolic syndrome and insulin resistance.

The 2011 Endocrine Society guidelines assert that vitamin D intakes above the current recommendations may be associated with better health outcomes. However, there is no consensus on the optimal 25(OH)D concentration necessary to minimize metabolic syndrome, insulin resistance and progression to diabetes. This trial is designed to prospectively identify optimal serum levels for reduction of cardiometabolic risk factors.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Please Note: All participants must be an employee of Allina Health or the spouse of an Allina employee.

Inclusion Criteria:

  • Vitamin D deficiency, defined as 25-OH vitamin D ≤ 25 ng/ml
  • Metabolic syndrome as defined by more than three or more of the following:

Elevated waist circumference

  • Men — Equal to or greater than 40 inches
  • Women — Equal to or greater than 35 inches
  • Elevated serum triglycerides (≥150 mg/dL)
  • Men — Less than 40 mg/dL
  • Women — Less than 50 mg/dL
  • Elevated blood pressure (≥130/85 or use of medication for hypertension)
  • Elevated fasting glucose (≥100 mg/dL or use of medication for hyperglycemia)

Exclusion Criteria:

  • Known cardiovascular disease defined as current or prior coronary heart disease, stroke/transient ischemic attack, heart failure, or peripheral vascular disease.
  • During the study, addition of any medications known to change outcome measures including medications or supplements for hyperlipidemia, hypertension, weight loss, diabetes.
  • Current Vitamin D supplementation beyond that found in a multivitamin (400 IU)
  • Current calcium supplementation greater than 600 mg
  • Untreated blood pressure greater than 159/99 at baseline
  • Treated blood pressure greater than 150/90 at baseline
  • Any condition which could limit the ability to complete and comply with 6-month study
  • Unwillingness or inability to comply with study requirements
  • Known allergy to coconut or coconut oil
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01545830

Contact: Shaina Biron 612-863-8936
Contact: Gregory Plotnikoff, MD 612-863-6274

United States, Minnesota
Allina Health Recruiting
Minneapolis, Minnesota, United States, 55407
Contact: Shaina Biron    612-863-8404   
Principal Investigator: Gregory A Plotnikoff, MD, MTS         
Sub-Investigator: Jeffery Dusek, PhD         
Sponsors and Collaborators
Allina Health System
Principal Investigator: Gregory Plotnikoff, MD Allina Health
Study Director: Jeffery Dusek, PhD Allina Health
Study Director: Shaina Biron Allina Health
  More Information

Responsible Party: Greg Plotnikoff, Senior Consultant, Allina Center for Healthcare Research and Innovation, Allina Health System Identifier: NCT01545830     History of Changes
Other Study ID Numbers: SPA ID 3607 
Study First Received: February 28, 2012
Last Updated: March 6, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Allina Health System:
Metabolic syndrome
Insulin resistance
Vitamin D deficiency

Additional relevant MeSH terms:
Metabolic Syndrome X
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Pathologic Processes
Vitamin D
Bone Density Conservation Agents
Growth Substances
Physiological Effects of Drugs processed this record on May 22, 2016